Oncology

Latest News

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

This research highlights the key factors, like leadership buy-in, mandatory protocols, and electronic health record workflows, that influence the effective collection of data on sexual orientation and gender identity in outpatient oncology clinics to improve patient-centered care.

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com

Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

By Jared Kaltwasser

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

By Jared Kaltwasser

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

June 24th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

June 24th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Peter Bach, MD, MAPP, Talks About Improving Quality in Cancer Care

November 19th 2012

Peter Bach, MD, MAPP, Talks About Improving Quality in Cancer Care

Peter B. Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Attending Physician, Memorial Sloan-Kettering Cancer Center, states that any organizational change that shifts payment and risk to providers will improve quality.

November 19th 2012

Automated Telephone Calls to Enhance Colorectal Cancer Screening: Economic Analysis

David H. Smith, RPh, PhD Adrianne C. Feldstein, MD, MS Nancy Perrin, PhD A. Gabriela Rosales, MS David M. Mosen, PhD, MPH Elizabeth G. Liles, MD Jennifer L. Schneider, MPH Jennifer E. Lafata, PhD Ronald E. Myers, PhD Russell E. Glasgow, PhD

Automated telephone calls can increase colorectal cancer screening rates at a cost of about $40 per additional screen.

Mark Fendrick, MD, Discusses Value-Based Insurance Design

November 19th 2012

Mark Fendrick, MD, Discusses Value-Based Insurance Design

Dr. Mark Fendrick, MD, Professor of Medicine and Health Management and Policy, Schools of Medicine and Public Health, University of Michigan, Co-Editor-in-Chief, The American Journal of Managed Care, says that there are levers organizations and stakeholders can pull to achieve the goal of improving quality and value in cancer care.

Michael Chernew, PhD, Discusses Challenges in Oncology Management

November 16th 2012

Michael Chernew, PhD, Discusses Challenges in Oncology Management

Michael Chernew, PhD, Professor of Health Care Policy, Harvard Medical School, Vice Chairman, MEDPAC, Co-Editor-in-Chief, The American Journal of Managed Care, says that patients want access to expensive drugs that can help expand and improve their lives.

Ira Klein, MD, Discusses Quality Measures in Oncology

November 16th 2012

Ira Klein, MD, Discusses Quality Measures in Oncology

Ira Klein, MD, MBA, FACP, Chief Medical Officer, National Accounts Clinical Sales & Strategy, Aetna, addresses measurement programs used in oncology.

Dennis Scanlon, PhD, Addresses the Importance of Payer/Provider Relationships

November 16th 2012

Dennis Scanlon, PhD, Addresses the Importance of Payer/Provider Relationships

Dennis Scanlon, PhD, Professor of Health Policy and Administration, The Pennsylvania State University, says it is very important to bridge the gap between providers and payers in oncology management.

November 13th 2012

Celgene Stock Soars on Promising Pancreatic Cancer Drug Data

November 12th 2012

Not Enough Cancer Drugs, Too Many Price Controls

October 29th 2012

Pricey New Prostate Cancer Therapy Raises Questions About Safety, Cost

October 24th 2012

Change to FIT Increased CRC Screening Rates: Evaluation of a US Screening Outreach Program

Elizabeth G. Liles, MD, MSCR Nancy Perrin, PhD Ana Gabriela Rosales, MS Adrianne C. Feldstein, MD, MS David H. Smith, RPh, MHA, PhD David M. Mosen, PhD, MPH Jennifer L. Schneider, MPH

Fecal immunochemical testing resulted in higher colorectal cancer screening rates than did guaiac fecal occult blood tests, with less dependence on office visits.

Aimee Tharaldson, PharmD, Identifies Trends in the Specialty Pharmacy Market

October 11th 2012

Aimee Tharaldson, PharmD, Identifies Trends in the Specialty Pharmacy Market

In this video, Aimee Tharaldson, PharmD, discusses some of the current trends in the specialty pharmacy market. In addition, Dr. Tharaldson specifically comments on the oncology pipeline, which currently has the most activity.

October 11th 2012

Therapeutic Vaccine Shows Potential in Fighting Cervical Cancer

October 10th 2012

3-D Mammograms Offer a New Option for Breast Cancer Screening

October 5th 2012

The Evolving Role of the Pharmacist in Oncology Care

The role of the pharmacist in the care of patients with cancer is evolving. Pharmacists can help optimize treatment outcomes for each patient through use of patient-specific and disease-specific strategies.

October 3rd 2012

Cancer Treatment Speeded by Genome Superhighway: Creator

October 3rd 2012

Prostate-Cancer Test May Reduce Repeat Biopsies: Study

October 1st 2012

Roche's Breast Cancer Franchise Boosted by Trial Data

September 27th 2012

Five-Cent Diabetes Pill From 1958 May Be New Cancer Drug

September 20th 2012

Crizotinib Active in ALK-Positive Pediatric Cancer

September 20th 2012

Oncology Leaders Praise Health Law Ruling-With Caveats

Beth Fand Incollingo

September 20th 2012

State-Level Projections of Cancer-Related Medical Care Costs: 2010 to 2020

Justin G. Trogdon, PhD Florence K. L. Tangka, PhD Donatus U. Ekwueme, PhD Gery P. Guy Jr, PhD Isaac Nwaise, PhD Diane Orenstein, PhD

State-level estimates of the number of people treated for cancer and the average cost of their treatment by state from 2010 through 2020.

September 20th 2012

How Can We Get Better Value in End-of-Life Care?

Stanton R. Mehr

September 20th 2012

Down the Road for Breast Cancer

Michael Marlan Mohundro, PharmD Brice Labruzzo Mohundro, PharmD

Targeted Therapies to Further Improve Outcomes

September 20th 2012

How Payers and Oncologists Really Feel About Oncology Pathways

Kim Farina, PhD

September 20th 2012

Partnering With a Payer to Develop a Value-Based Medical Home Pilot: A West Coast Practice's Experience

Linda D. Bosserman, MD, FACP Diana Verrilli Wendy McNatt

September 20th 2012

Oncology Patient-Centered Medical Home

John D. Sprandio, MD, FACP

September 20th 2012

Medical Drug Benefit Management in the Pathway Era

Kim Farina, PhD

September 19th 2012

Outpatient-Shopping Behavior and Survival Rates in Newly Diagnosed Cancer Patients

Shang-Jyh Chiou, DrPH Shiow-Ing Wang, PhD Chien-Hsiang Liu, PhD Chih-Liang Yaung, PhD

Higher incomes, higher comorbidity scores, and more advanced cancer were associated with outpatient-shopping behavior in Taiwanese patients.

September 18th 2012

Implementation of Cancer Clinical Care Pathways

Bruce A. Feinberg, DO James Lang, PharmD, MBA James Grzegorczyk, MS, RPh Donna Stark, RPh, MBA Thomas Rybarczyk, RN, BSN Thomas Leyden, MBA Joseph Cooper Thomas Ruane, MD Scott Milligan, PhD

September 18th 2012

Trends in the 2012 Eisai Oncology Digest: Counseling and Communication of Cancer Treatment

...

176 177 178 179 180 181 182 183 184

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions